Activity of Nuclear Factor of Activated T Cells Is Independent of the Number of Peripheral Lymphocytes in FTY720-Treated Patients

Transplantation Proceedings

Volumn 40, Issue 5, 2008, Pages 1416-1418

  Sommerer, C ^a   Morath, C ^a   Giese, T ^a   Meuer, S ^a   Zeier, M ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; CREATININE; CYCLOSPORIN A; FINGOLIMOD; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2; MYCOPHENOLIC ACID; STEROID; TRANSCRIPTION FACTOR NFAT;

ARTICLE; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HUMAN; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LOW DRUG DOSE; LYMPHOCYTOPENIA; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; QUANTITATIVE ASSAY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

CYCLOSPORINE; GENE EXPRESSION REGULATION; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERFERON TYPE II; INTERLEUKIN-2; KIDNEY TRANSPLANTATION; LYMPHOCYTE ACTIVATION; LYMPHOPENIA; METHYLPREDNISOLONE; NFATC TRANSCRIPTION FACTORS; PROPYLENE GLYCOLS; RNA, MESSENGER; SPHINGOSINE; T-LYMPHOCYTES;

EID: 45449099491     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2008.01.067     Document Type: Article

References (8)

1. Giese T., Zeier M., and Meuer S. Analysis of NFAT-regulated gene expression in vivo: a novel perspective for optimal individualized doses of calcineurin inhibitors. Nephrol Dial Transplant 19 suppl 4 (2004) 55
2. Sommerer C., Konstandin M., Dengler T., et al. Pharmacodynamic monitoring of cyclosporine A in renal allograft recipients shows a quantitative relationship between immunosuppression and the occurrence of recurrent infections and malignancies. Transplantation 82 (2006) 1280
3. Tedesco-Silva H., Pescovitz M.D., Cibrik D., et al. Randomized controlled trial of FTY720 versus MMF in de novo renal transplantation. Transplantation 82 (2006) 1689
4. Kahan B.D. FTY720: from bench to bedside. Transplant Proc 36 suppl 2 (2004) 531S
5. Mandala S., Hajdu R., Bergstrom J., et al. Alteration of lymphocyte trafficking by sphingosine-1-phosphatase receptor agonists. Science 296 (2002) 346
6. Kahan B.D., Karlix J.L., Ferguson R.M., et al. Pharmacodynamics, pharmacokinetics and safety of multiple doses of FTY720 in stable renal transplant patients: a multicenter randomized, placebo-controlled, phase I study. Transplantation 76 (2003) 1079
7. Dragun D., Fritsche L., Boehler T., et al. FTY720 early clinical experience. Transplant Proc 36 suppl 2S (2004) 544S
8. Salvadori M., Budde K., Charpentier B., et al. FTY720 versus MMF with cyclosporine in de novo renal transplantation: a 1-year, randomized controlled trial in Europe and Australia. Am J Transplant 6 (2006) 2912